ACTH 1-17 effects in the chemotherapy of advanced solid tumors.
The effect of administration of a synthetic ACTH analogue (ACTH 1-17, Synchrodyn) in the chemotherapy of advanced-phase solid tumors was studied. In this preliminary report the following data are evaluated: response rate; occurrence of toxic effects; performance status of patients; several immunological parameters. The administration of Synchrodyn seems mainly to influence the lymphocyte subpopulations and the occurrence of toxic effects. A final evaluation of the role that may be played by chronotherapy in the treatment of tumors must await further studies on the clinical response and tolerance.